Companies · Biotechnology

Tetrous, Inc.

SHERMAN OAKS · Biotechnology

Diligence memoA one-page analyst read on Tetrous, Inc. — recommendation, valuation, rhythm, risks.
$445K
Total raised · real
1
Rounds
1.0×
Latest step-up
Top 92%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Tetrous, Inc. looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.90× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
  • Within the normal band (90% of peer median) for its niche.
At-risk
  • Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Tetrous, Inc. is one of 4291 Biotechnology companies tracked from SHERMAN OAKS. By capital raised it ranks in the long tail (ahead of 9% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(c)
Reg D exemption
2
Investors (latest)
2019
Year incorporated
2023-12-12
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3M$2.5M$3.8M$5.0MPre-Seed · 2023-12-12 Raised $445K (real) Modeled valuation $2.9M (est)$445K$2.9MPre-Seed2023Pre-Seed · 2023-12-12 Raised $445K (real) Modeled valuation $2.9M (est)$445K$2.9MPre-Seed2023+$445KCumulative $889K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$445K · 2023
Pre-Seed extension$445K · 2023

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$2.9M
Base estimate est.
$237K
Conservative case
$11.5M
Upside case
$2.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $2.9M · 2023-12-122023Pre-Seed · modeled $2.9M · 2023-12-122023
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
2.5 yr
Elapsed time used
2.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
2.6 yr
On record since
2023
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$445K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.1× above median
This company$445K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$2.9M
Sector median$64.2M

Raised more than 9% of sector peers (real $). Modeled value above 7% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #105 of 185.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)TissueMill Technologies LLC · Pre-Seed Raised $1.0M · modeled $18.2M (est)Aldebaran Therapeutics, Inc. · Pre-Seed Raised $800K · modeled $16.3M (est)BullFrog AI Holdings, Inc. · Pre-Seed Raised $866K · modeled $15.4M (est)Vesicle Therapeutics Inc. · Pre-Seed Raised $800K · modeled $14.8M (est)TAUC3 Biologics Ltd · Pre-Seed Raised $839K · modeled $14.4M (est)UCHU Biosensors, Inc. · Pre-Seed Raised $828K · modeled $13.1M (est)BackStop Neural, Inc. · Pre-Seed Raised $884K · modeled $12.9M (est)Virocell Biologics Ltd · Pre-Seed Raised $993K · modeled $12.9M (est)PurCell Bio, Inc · Pre-Seed Raised $841K · modeled $12.6M (est)MicroVizual Inc. · Pre-Seed Raised $750K · modeled $12.0M (est)NeuroX Innovations Inc. · Pre-Seed Raised $1.2M · modeled $11.9M (est)NeuroDex Inc · Pre-Seed Raised $1.3M · modeled $11.8M (est)Tetrous, Inc. (this company) Raised $445K · modeled $2.9M (est)Tetrous, Inc.
CompanyStageRaised · realValue · estvs peer med.
TissueMill Technologies LLCPre-Seed$1.0M$18.2M5.66×
Aldebaran Therapeutics, Inc.Pre-Seed$800K$16.3M5.05×
BullFrog AI Holdings, Inc.Pre-Seed$866K$15.4M4.78×
Vesicle Therapeutics Inc.Pre-Seed$800K$14.8M4.60×
TAUC3 Biologics LtdPre-Seed$839K$14.4M4.48×
UCHU Biosensors, Inc.Pre-Seed$828K$13.1M4.07×
BackStop Neural, Inc.Pre-Seed$884K$12.9M4.01×
Virocell Biologics LtdPre-Seed$993K$12.9M4.00×
PurCell Bio, IncPre-Seed$841K$12.6M3.91×
MicroVizual Inc.Pre-Seed$750K$12.0M3.73×
NeuroX Innovations Inc.Pre-Seed$1.2M$11.9M3.69×
NeuroDex IncPre-Seed$1.3M$11.8M3.67×
Tetrous, Inc. this companyPre-Seed$445K$2.9M0.90×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$445K2023-12-12$2.5M$2.9M90%
Pre-Seed$445K2023-12-12$2.5M$2.9M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$445K2023-12-12
    • First recorded raise — entered as Pre-Seed.
    • 2 investors on this round.
  2. Pre-Seed$445K2023-12-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
Intelligence
Modeled next raise
$445K
Modeled next size est.range $445K$711K
1.0×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Bradley E. Patt2 other2023-12
Frank E. Phillips1 other2023-12
Andy E. Carter2023-12
Gunnar E. Andersson2023-12
Jan E. Iwanczyk2023-12
John E. Bojanowski2023-12
Nikhil E. Verma2023-12
Simon E. Berry2023-12
Registry & provenance

Tetrous, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2002357
SEC CIK
2019
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Tundra Targeted Therapeutics, Inc.BiotechnologyPre-Seed$444K$1.2Msame sector · same stage
Autism Therapeutics LtdBiotechnologyPre-Seed$450K$600Ksame sector · same stage
Immorta Bio, Inc.BiotechnologyPre-Seed$450K$3.1Msame sector · same stage
Prana Biosciences Inc.BiotechnologyPre-Seed$450K$756Ksame sector · same stage
SIMPLE iDEAS, Inc.BiotechnologyPre-Seed$450K$600Ksame sector · same stage
Bondwell Technologies LPBiotechnologyPre-Seed$451K$3.1Msame sector · same stage
Ilico Genetics, Inc.BiotechnologyPre-Seed$458K$5.1Msame sector · same stage
Elysia Creative Biology, Inc.BiotechnologyPre-Seed$465K$1.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
TeVido BioDevices, Inc.BiotechnologySeed$63.1M89%
Tekv Holdings LLCBiotechnologySeed$55.4M88%
Tetragenetics IncBiotechnologySeed$39.8M88%
SutroVax, Inc.BiotechnologySeries D+$4.5B88%
Tetra Discovery Partners, Inc.BiotechnologySeries B$1.4B87%
Tetherex Pharmaceuticals CorpBiotechnologySeries C$1.8B86%
Torus Biosystems, Inc.BiotechnologySeries B$706.3M86%
Neurotrope, Inc.BiotechnologySeries B$972.6M86%
Frequently asked
How much funding has Tetrous, Inc. raised?
Tetrous, Inc. has raised approximately $445K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Tetrous, Inc.'s estimated valuation?
Provath's modeled valuation for Tetrous, Inc. is approximately $2.9M (modeled range $237K–$11.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Tetrous, Inc. at?
Tetrous, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue Dec 12.
What does Tetrous, Inc. do and where is it based?
Tetrous, Inc. operates in the Biotechnology sector, based in SHERMAN OAKS.
Explore related

See where Tetrous, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Tetrous, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.